NCT02747888 Hereditary Risk Factors for Thyroid Cancer
| NCT ID | NCT02747888 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Thyroid Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2016-03-01 |
| Primary Completion | 2029-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2016-03-01 with a primary completion date of 2029-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes. Researchers are studying thyroid cancer in children and families, with a particular interest in understanding genes and other factors that may put individuals at risk for developing thyroid cancer and thyroid nodules. * In this study, family and medical history information is collected alongside a blood or saliva sample for genetic studies. * Individuals with a past or present childhood thyroid cancer/nodule or a thyroid cancer suspected to be inherited in their family are invited to participate.
Eligibility Criteria
Inclusion Criteria: * Individual pediatric patient with current or previous known or suspected thyroid cancer or nodule(s). * Individual adult patient with current or previous known or suspected thyroid cancer or nodule(s) if they come from a family with a high suspicion of hereditary cancer (as below). * Individuals from families with a high suspicion of hereditary thyroid cancer: * Families with a current or previous diagnosis of a thyroid cancer/nodule occurring in childhood (\<18 years old). * Families with a high suspicion of hereditary thyroid cancer/nodules other than above to include: * Families with thyroid cancer in multiple individuals * Families with thyroid cancer and a known genetic syndrome * Families with thyroid cancer and a suspected genetic syndrome (e.g. multiple childhood cancers in the family, multiple primary cancers, multiple endocrinopathies, etc.) Exclusion Criteria: * Individuals who are unable to give informed consent. * Individuals who are unable to complete study materials.
Contact & Investigator
Junne Kamihara, MD, PhD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT02747888 clinical trial?
This trial is open to participants of all sexes, studying Thyroid Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02747888 currently recruiting?
Yes, NCT02747888 is actively recruiting participants. Contact the research team at junne_kamihara@dfci.harvard.edu for enrollment information.
Where is the NCT02747888 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT02747888 clinical trial?
NCT02747888 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Junne Kamihara, MD, PhD at Dana-Farber Cancer Institute. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.